We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hvivo Plc | LSE:HVO | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.10 | 0.35% | 28.50 | 28.00 | 29.00 | 28.50 | 28.25 | 28.25 | 1,552,155 | 12:12:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 56.04M | 16.12M | 0.0237 | 12.03 | 193.23M |
TIDMVENN
RNS Number : 5057L
Venn Life Sciences Holdings PLC
12 January 2016
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Contracts worth EUR 3.4m signed with US Biotech
Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that they have signed new contracts worth over EUR3.4m with a leading US based Biotechnology client.
These contracts are extensions of an existing Phase II programme. The work will commence immediately and run until the end of 2017 in multiple US and European sites.
Speaking about the agreement, Venn CEO, Tony Richardson stated: "During 2015, I commented that executing our work to a consistent high standard would bring significant rewards and I am delighted to be able to show the concrete evidence of this. This is the second extension of what is a complex international programme and this endorsement is well deserved by our team. It is particularly pleasing to win this business at the commencement of the new year. 2015 was a year of significant growth at Venn and new business wins of this magnitude will enable us to continue expanding our business."
Enquiries:
Venn Life Sciences Holdings Plc www.vennlifesciences.com Tony Richardson, Chief Executive Officer Tel: +353 154 99 341 Jonathan Hartshorn, Chief Financial Officer Tel: +353 153 93 269 Orla McGuinness, Marketing Manager Tel: +353 153 93 269 Zeus Capital (Nominated Adviser and Joint Tel: +44 (0) 20 3829 5000 Broker) Andrew Jones / Phil Walker Dominic Wilson / Alex Davis Hybridan LLP (Joint-Broker) Claire Louise Noyce Tel: 020 3764 2341 Walbrook PR Ltd Tel: 020 7933 8787 or venn@walbrookpr.com Lianne Cawthorne Mob: 07584 391 303
About Venn Life Sciences Limited: Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn Life Sciences specialises in rapid deployment and management of multisite projects, across all phases. Venn Life Sciences also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.
For more information about the Company, please visit: www.vennlifesciences.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCQFLFFQFFEBBD
(END) Dow Jones Newswires
January 12, 2016 02:00 ET (07:00 GMT)
1 Year Hvivo Chart |
1 Month Hvivo Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions